TrialPloS one2018

The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease.

Esther Kuperus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.